A New Allelic Variant in the PANK2 Gene in a Patient with Incomplete HARP Syndrome

Article information

J Mov Disord. 2020;13(3):229-231

Publication date (electronic) : 2020 July 14

doi : https://doi.org/10.14802/jmd.19071

Myriam Ley Martos¹, María Jesús Salado Reyes¹, Rosario Marín Iglesias², Carmen Gutiérrez Moro¹, Manuel Lubián Gutiérrez^,1, Lorena Estepa Pedregosa³

¹Department of Neuropediatrics, Puerta del Mar Hospital, Cádiz, Spain

²Department of Genetics, Puerta del Mar Hospital, Cádiz, Spain

³Department of Critical Care, Puerta del Mar Hospital, Cádiz, Spain

Corresponding author: Manuel Lubián-Gutiérrez, MD Department of Neuropediatrics, Puerta del Mar Hospital, Avda. Ana de Viya n 21, Cádiz 11009, Spain / Tel: +34-697522063 / Fax: +34-956002318 / E-mail: manu.lubian@gmail.com

Received 2019 October 16; Revised 2019 December 11; Accepted 2020 May 8.

Dear Editor,

Pantothenate kinase-associated neurodegeneration (PKAN) is a rare autosomal recessive disease characterized by iron deposition in the basal ganglia, primarily in the globus pallidus and substantia nigra. Common clinical manifestations include dystonia, parkinsonism, spasticity, neuropsychiatric disorders and retinal degeneration. PKAN is included in the spectrum of disorders related to neurodegeneration with brain iron accumulation (NBIA), which includes eleven diseases.

We present a patient with a phenotypic syndrome known as HARP syndrome (hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration), without hypoprebetalipoproteinemia in our case, with a new allelic variant in the PANK2 gene, consisting of a deletion of eight nucleotides (c.502-512delAGCGCGTC) in exon 1, which has not been described previously. To the best of our knowledge, no other mutations in exon 1 of the PANK2 gene have been reported in patients with HARP syndrome.

A 5-year-old boy presented with delay in motor skills. His parents were nonconsanguineous, and he had one healthy sibling. His perinatal and family history were normal. He showed generalized dystonia and hypomimicry, spasticity and speech difficulty but no cognitive problems. Kidney and hepatic function, serum copper, ceruloplasmin and lipids were normal. Conventional EEG revealed a generalized slowing pattern. A cerebrospinal fluid study was normal. Magnetic resonance imaging (MRI) demonstrated subtle linear bilateral hypointense lesions in the globus pallidus on T2-weighted sequences with a blooming artifact on susceptibility weighted imaging (Supplementary Figure 1 in the online-only Data Supplement). This picture was not clearly recognizable as a characteristic “eye-of-the-tiger” sign.

Ocular fundoscopy was compatible with retinitis pigmentosa, and a peripheral blood smear exhibited 6% acanthocytes (Supplementary Figure 2 in the online-only Data Supplement). Nutritional status was normal, and we excluded other possible conditions that could cause acanthocytosis.

PANK2 gene (20p13) sequencing performed in 2018 revealed two compound heterozygous variants. The first was a frameshift mutation consisting of a deletion of eight nucleotides in exon 1 of the gene (c.502-512delAGCGCGTC). This change produces the replacement of serine for glycine at codon 169, which generates a stop signal nine amino acids later (p.Ser169GlyfsTer9). This variant had not been previously reported (HGMD, NCBI, ClinVAR). Nonetheless, predictor genetic databases classified this mutation as likely pathogenic, taking into account that it is a frameshift mutation with an impact on PANK2 gene function. Given that HARP syndrome is inherited in an autosomal recessive manner, the phenotype of our patient can be explained by two pathogenic mutations in PANK2. Other variants in exon 1 of the PANK2 gene have been described previously as causative of PKAN; however, there are no cases of exon 1 mutations described in HARP syndrome (Table 1) [1-6].

Table 1.

Reported cases of HARP syndrome

The other variant found was a missense mutation in exon 6, causing a glycine to arginine change in position 521 of the protein (p.Gly521Arg; c.1561G>A). This mutation had been previously described as a pathogenic variant [7]. Segregation analysis revealed that each of the parents was heterozygous for one of the two variants (Supplementary Figure 3 in the online-only Data Supplement). Neither of them was symptomatic.

Our patient had a rapidly progressive evolution with severe dystonia despite treatment with oral and intrathecal baclofen, clonazepam, trihexyphenidyl and vitamin B5 (pantothenic acid). Percutaneous endoscopic gastrostomy was performed to improve nutritional intake. He is currently being treated with phospho-pantothenic replacement therapy, with no relevant results to report due to the short duration of treatment to date.

PKAN (NBIA1) is the most common type of NBIA and has a wide phenotypic spectrum. To date, 176 pathogenic mutations in the PANK gene have been reported. The estimated incidence of PKAN is 3/1,000,000. In the classic form, symptoms appear before 6 years old and are rapidly progressive. HARP syndrome is an allelic variant of this entity [1,2] with an autosomal recessive inheritance. It is characterized by iron accumulation in the basal ganglia, acanthocytosis, retinitis pigmentosa and hypolipoproteinemia. As in other forms of NBIA, iron storage in the basal ganglia creates the typical “eye-of-the-tiger” sign on MRI. Nevertheless, this radiological finding could be missing in early stages of the disease. HARP syndrome was initially described by Higgins et al. in 1992 [3]. They reported a case of a young woman with generalized dystonia since childhood associated with retinitis pigmentosa, acanthocytosis and hypolipoproteinemia. In the same decade, Orrell et al. [4] reported a similar patient. PANK gene mutations were found in both cases, and HARP syndrome was described as a variant of PKAN disease.

In our case, apolipoprotein B deficiency was not present. This fact has been reported previously [4,5]. To the best of our knowledge, the genetics of cases without hypolipoproteinemia have not been studied comprehensively. The newly found variant c.502-512delAGCGCGTC in our patient may be an important report of incomplete HARP syndrome (Table 1) [1-6]. A limitation of our case is that no functional studies have been carried out with this new allelic variant.

To date, there is no curative treatment, and palliative therapy offers poor results. The present case report adds a probably pathogenic variant to those previously described in HARP syndrome. Better knowledge of the genetics and pathophysiology, including the role of iron accumulation in specific brain areas and cellular oxidation, may help lead to a new approach and effective therapy in the future for patients with PKAN.